Europe, Middle East & Africa Substance Abuse Treatment Market - Growth, Trends, and Forecasts (2020-2025)

The EMEA (Europe, Middle East & Africa) substance abuse treatment market is expected to witness a CAGR of 9.0%, over the forecast period. Certain factors that are driving the market growth include rising drug awareness campaigns and prevention programs, a high number of addicted population, and technological advancement in the diagnostics industry.

The rise in the drug awareness campaigns and associated prevention programs is one of the primary factors linked to the growth of the market studied. It includes rising patient awareness, higher treatment-seeking rate with increased government intervention, and encouragement to curb substance abuse in several countries. Medications that help avoid relapse and control drug cravings also propel the market studied. Additionally, an increasing number of treatment centers that have collaborations with private recovery facilities are entering the market, thus helping in the expansion of treatment access to a higher number of people in the society. Furthermore, other factors, such as a high number of addicted population and technological advancement in the diagnostics industry, are transforming and driving this market.

However, the discontinuation of behavioral therapies often leads to a relapse of addiction, which is a crucial factor hindering the growth of the market. Many patients opt for outpatient care for the treatment of drug dependence.In addition, the high reluctance of individuals for accessing treatment modalities and poor treatment compliance in some countries hinder the growth of the market studied.

Key Market Trends

Nicotine Replacement Treatment is Expected to Hold Significant Market Share in the Tobacco/Nicotine Addiction Treatment Segment

The nicotine in tobacco leads to actual physical dependence. This can cause unpleasant withdrawal symptoms when a person tries to quit. Nicotine replacement therapy (NRT) offers nicotine in the form of gum, patches, sprays, inhalers, or lozenges, without other harmful chemicals in tobacco. Nicotine gum has been in use for around 30 years, to help smokers quit smoking. Many studies have shown using nicotine gums, or any other nicotine replacement therapy, can nearly double the chances of quitting smoking. Europe has the highest prevalence of tobacco smoking among adults (28%), and some of the highest prevalence of tobacco use by adolescents. While tobacco use was previously exclusive to males, the gap in the prevalence between male and female adults is now very small (< 5%), in countries, such as Denmark, Ireland, the Netherlands, Norway, Sweden, and the United Kingdom. Products, such as Nicotex (Nicotine chewing gums), are available as OTC products and are widely used by people who actively want to quit smoking. Individuals smoking 20 or more cigarettes a day should use the 4 mg Nicotex gum, which needs to be prescribed by a physician. Individuals smoking 20 or less cigarettes a day should use the 2 mg Nicotex gum. Nicotine gums are much safer when compared to smoking, though they too have few side effects as any other drug. However, their benefits outdo the side effects. These Nicotex gums may witness strong demand in the coming years.

Competitive Landscape

The market is highly competitive and consists of a number of major players. Companies, like Alkermes PLC, Allergan, GSK PLC, Mallinckrodt LLC, Mylan Laboratories, Pfizer Inc., Purdue Pharma LP, Sanofi Aventis SA, and Teva Pharmaceuticals, among others, hold the substantial share in the market studied.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.